Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9548953 | 0.98 | PTPN22 (0.48) | PTPN22EP300KAT2BKAT8ERN1 | |
| SCHEMBL9827957 | 0.83 | ERN1 (0.59) | PTPN22EP300KAT2BKAT8ERN1 | |
| SCHEMBL3240722 | 0.79 | POLB (0.53) | EP300KAT2BKAT8ERN1KDM4E | |
| SCHEMBL27332884 | 0.79 | EP300 (0.53) | EP300KAT2BKAT8ERN1KDM4E | |
| SCHEMBL11478088 | 0.79 | EP300 (0.44) | EP300KAT2BKAT8ERN1KDM4E | |
| SCHEMBL24608162 | 0.79 | AXL (0.44) | EP300KAT2BKAT8ERN1KDM4E | |
| SCHEMBL17308538 | 0.79 | MAPK10 (0.44) | EP300KAT2BKAT8ERN1KDM4E | |
| SCHEMBL29751627 | 0.79 | AXL (0.44) | EP300KAT2BKAT8ERN1KDM4E | |
| SCHEMBL672509 | 0.78 | CLK1 (0.54) | KDM4EMAPKAPK2CLK1DYRK1AMAPK10 | |
| SCHEMBL29569821 | 0.78 | CLK1 (0.54) | KDM4EMAPKAPK2CLK1DYRK1AMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4742053-A | ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-05-03 | — | — | US | claimed |
| EP-0182210-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-05-28 | — | — | EP | claimed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-5194433-A | Improved effectiveness against resistant bacteria | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0485808-A2 | Antibiotic C-3 catechol-substituted cephalosporin compounds, compositions and use thereof | Bristol-Myers Squibb Company (US) | 1992-05-20 | — | — | EP | disclosed |
| EP-0182210-B1 | CEPHALOSPORIN DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4742053-A | ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0182210-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | PTPN22 2156/4885EP300 576/4885KAT2B 1774/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | PTPN22 810/4885EP300 89/4885KAT2B 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.